VA Cooperative Studies Program Coordinating Center, Boston, MA 02130, USA.
Department of Radiation Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH 44105, USA.
Curr Pharm Des. 2022;28(21):1695-1702. doi: 10.2174/1381612828666220418132847.
Vitamin D is an important immune-modulator with anti-inflammatory properties. While this prohormone has been studied extensively in the prevention and treatment of COVID-19, findings have been inconsistent regarding its overall benefit in patients hospitalized with COVID-19. Most studies to date have been observational in nature, not accounting for the use of corticosteroids. Furthermore, the few randomized clinical trials designed to examine the effect of vitamin D supplementation on COVID-19 outcomes have been relatively small and thus insufficiently powered to assure a balance of corticosteroid use between study arms. The current perspective addresses the interaction of vitamin D and corticosteroids as a potential explanation for the divergent results reported in the literature. Future research on vitamin D and COVID-19 will benefit by considering this interaction, especially among hospitalized patients requiring oxygen and mechanical ventilation.
维生素 D 是一种重要的免疫调节剂,具有抗炎特性。虽然这种前激素已在 COVID-19 的预防和治疗中被广泛研究,但关于其在 COVID-19 住院患者中的整体益处的研究结果一直不一致。迄今为止,大多数研究都是观察性的,没有考虑到皮质类固醇的使用。此外,为数不多的旨在研究维生素 D 补充剂对 COVID-19 结局影响的随机临床试验规模相对较小,因此不足以确保研究组之间皮质类固醇使用的平衡。当前的观点探讨了维生素 D 和皮质类固醇之间的相互作用,这可能是文献中报告的不同结果的一个解释。未来关于维生素 D 和 COVID-19 的研究将受益于考虑这种相互作用,特别是在需要吸氧和机械通气的住院患者中。